The aim of the trial is to investigate the safety and feasibility of the NanoKnife System in treating patients with pancreatic cancer.

The study enrolled subjects with tumors of a size no greater than 4 cm, who are unresponsive to chemotherapy as evaluated with either computed tomography (CT) or magnetic resonance (MR) imaging, and having not taken any chemotherapy agents within 14 days of treatment with the NanoKnife system.

In the trial, the primary endpoint is safety determined at 90-days post treatment, while secondary endpoint includes determination of efficacy at 90-days, through tumor response assessment with imaging.

AngioDynamics president and CEO Joseph DeVivo said through the European trial and other previous studies, they are building a body of evidence that helps them better understand the NanoKnife system’s capabilities.

"We look forward to seeing published scientific results from this European pancreas trial in the next six to nine months," DeVivo added.